How should I manage an elderly female patient on valproic acid who has a trough serum concentration of 38 µg/mL (subtherapeutic)?

Management of Subtherapeutic Valproic Acid Level (38 µg/mL) in an Elderly Female

Increase the valproic acid dose immediately, as a trough level of 38 µg/mL is below the therapeutic range of 50–100 µg/mL and places this elderly patient at risk for breakthrough seizures.

Immediate Dose Adjustment Strategy

• Increase the daily dose by 250–500 mg (approximately 5–10 mg/kg/week increments) to achieve therapeutic concentrations of 50–100 µg/mL 1
• In elderly patients, dose escalation should proceed more slowly than in younger adults due to decreased unbound clearance and increased sensitivity to adverse effects 1
• Recheck the trough valproic acid level in 5–8 days after the dose adjustment, as steady-state concentrations are reached after approximately one week of maintenance therapy 2

Special Considerations in Elderly Patients

Pharmacokinetic Changes with Aging

• Total valproic acid clearance remains similar between elderly and younger patients, but protein binding is reduced in the elderly, resulting in higher free (active) drug fractions 3, 4
• The volume of distribution may be increased (0.19 vs 0.13 L/kg) and elimination half-life prolonged (14.9 vs 7.2 hours) in older patients compared to younger adults 3
• Normalized apparent clearance is 40% lower in elderly patients when corrected for albumin concentration, meaning elderly patients may require lower total doses to achieve the same therapeutic effect 4

Dosing Approach for This Patient

• Start with a conservative dose increase of 250 mg/day initially, then titrate upward based on clinical response and repeat drug levels 1
• Monitor for somnolence, dehydration, and reduced nutritional intake at each follow-up, as these adverse effects occur more frequently in elderly patients on valproic acid 1
• Consider checking serum albumin concentration, as low albumin (<42 g/L) can lead to misinterpretation of total valproic acid levels in elderly patients 4

Monitoring Protocol

Therapeutic Drug Monitoring Schedule

• Obtain a trough level (drawn immediately before the next dose) 5–8 days after each dose adjustment to assess whether therapeutic range has been achieved 2
• Once stable, question the patient about seizure occurrences at each follow-up visit to correlate drug levels with clinical efficacy 5
• If levels remain subtherapeutic despite dose increases, check for drug interactions with enzyme-inducing medications (phenytoin, carbamazepine, phenobarbital) or carbapenem antibiotics, which can reduce valproic acid concentrations 1, 3

Safety Monitoring in Elderly Patients

• Monitor fluid and nutritional intake closely, as elderly patients on valproic acid have higher rates of dehydration and weight loss associated with somnolence 1
• Assess for excessive somnolence at each visit; dose reduction or discontinuation should be considered if the patient develops decreased food/fluid intake or excessive sedation 1
• Check liver function tests periodically, as hepatotoxicity risk exists, though the ratio of 4-ene-VPA to VPA (threshold >10.03%) is a better predictor than total drug level 6

Common Pitfalls to Avoid

• Do not assume the patient is non-compliant without first confirming medication adherence through pill counts or pharmacy records; subtherapeutic levels may reflect true pharmacokinetic variability 5
• Do not rely solely on the "therapeutic range" of 50–100 µg/mL as an absolute predictor of efficacy, since some patients achieve seizure control at lower concentrations while others require higher levels 7, 6
• Do not increase doses too rapidly in elderly patients, as this population is more susceptible to dose-related adverse effects including thrombocytopenia (risk increases significantly at levels ≥110 µg/mL in females) 1
• Do not overlook drug interactions: carbapenem antibiotics can drop valproic acid levels to subtherapeutic ranges and precipitate seizures; alternative antibiotics should be strongly considered 1

Alternative Considerations

• If the patient develops intolerable adverse effects during dose escalation, consider switching to the controlled-release (extended-release) formulation, which may improve tolerability and allow once-daily dosing to enhance compliance in elderly patients 3
• If therapeutic levels cannot be achieved despite appropriate dosing, evaluate for enzyme-inducing co-medications (phenytoin, carbamazepine, phenobarbital, primidone) that increase valproic acid clearance 3
• In rare cases requiring very high doses (>4000 mg/day), autoinduction of valproic acid metabolism may occur, necessitating progressive dose increases over time 8

Target Therapeutic Range

• Aim for trough concentrations of 50–100 µg/mL, though the correlation between specific levels and clinical outcomes is imperfect 1, 7
• Concentrations above 100 µg/mL are associated with increased adverse reactions, including gastrointestinal symptoms, tremor, and thrombocytopenia 7, 1
• Recent evidence suggests that metabolite concentrations (particularly 2-PGA for efficacy and the 4-ene-VPA/VPA ratio for hepatotoxicity) may be better predictors of clinical outcomes than total valproic acid levels alone 6